Navigation Links
High-Dose Chemo Fails Against Small Cell Lung Cancers
Date:4/9/2008

Tripled dose was ineffective and toxic, so strategy should be abandoned, study says

WEDNESDAY, April 9 (HealthDay News) -- High-intensity chemotherapy does not improve the survival rate of patients with small cell lung cancer (SCLC), a new Swiss study concludes.

Testing on 140 patients in a randomized trial showed no statistically significant differences in survival rate or tumor size between groups receiving either standard or high doses of chemo over a three-year period. The findings were published online April 8 in the Journal of the National Cancer Institute.

Researchers thought upping the amount of chemotherapy might help the patients live longer because laboratory data had suggested that higher doses kill SCLC cells resistant to standard doses.

"The approach explored in the present trial succeeded in raising the peak dose, total dose and dose intensity of (the chemotherapy drugs) by threefold but has clearly been ineffective and highly toxic," the authors wrote. "As a result, this strategy should be abandoned."

SCLC accounts for almost 13 percent of lung cancer cases in the United States. While many patients initially respond to chemotherapy, most suffer disease recurrence relatively quickly.

The study, lead by Dr. Serge Leyvraz of the University Hospital in Lausanne, Switzerland, compared high-dose and standard-dose chemotherapy using the drug agents: ifosfamide, carboplatin and etoposide (ICE).

The survival rates in the group were similar: 18 percent of the high-dose patients were alive after three years, 19 percent of standard-dose patients survived. Tumor shrinkage was also similar in the two groups: 78 percent among the high-dose recipients and 68 percent in the standard-dose arm.

More information

The National Cancer Institute has more about lung cancer.



-- Kevin McKeever



SOURCE: Journal of the National Cancer Institute, news release, April 8, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
2. High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
3. High-Dose Chemo Helps Beat Rare Brain Cancer
4. Chemotherapy may be culprit for fatigue in breast cancer survivors
5. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
6. To evade chemotherapy, some cancer cells mimic stem cells
7. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
8. PET scans can accurately detect a breast tumors response to chemotherapy
9. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
10. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
11. Medicare modernization act did not change chemotherapy as feared
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... United Benefit Advisors (UBA), the nation’s ... to its growing list of Partner Firms. S.S. Nesbitt is headquartered in ... Huntsville and in between. , Harnessing the experience and insights of the agency’s ...
(Date:2/10/2016)... ... 2016 , ... AHRA: The Association for Medical Imaging Management ... will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, ... effectively communicate with their own organizational staff and leadership. , “I am ...
(Date:2/10/2016)... Palm Beach, Florida (PRWEB) , ... February 10, ... ... & Country Club) announced that it has been awarded the prestigious Distinguished Emerald ... the World award program conducted by BoardRoom magazine, one of the most respected ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week ... series of monitor mounts ever. , “Our goal was to develop a product ... install system that we have ever created.” said Darren Hulsey, Product Manager for Workrite ...
(Date:2/10/2016)... ... , ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman ... announcement Monday night, Feb. 8, prior to the evening session of the university’s 80th ... of GO! Camp, has been named director. Gayle McDonald, currently the assistant director of ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016 Urologix, the market leader for ... Benign Prostatic Hyperplasia (BPH), announces new private ownership and ... a medical device industry veteran of more than 20 ... Company.  Plymouth, Minn. ... ThermoTherapy™ and Prostiva® RF Therapy, will continue to be ...
(Date:2/10/2016)... -- A Worldwide Clinical Trials expert will present ... Park Plaza in London , 24-25 February ... future advances for late phase research on Wednesday, 24 Feb ... associate director of project management at Worldwide, will focus on ... and standards in late phase research. --> ...
(Date:2/10/2016)... DIEGO , Feb. 10, 2016  Visage ... Pro Medicus Ltd. (ASX: PME), has announced that the ... of Florida (UF) have selected the Visage 7 ... viewer of the Emergent/Critical Care Imaging SIMulation (SIM). ... in Diagnostic Imaging Program (WIDI), a multi-faceted and ...
Breaking Medicine Technology: